Keynote 024 Pfs

Keynote 024 Pfs. Pembrolizumab (keytruda) continued to demonstrate at trend toward improved overall survival (os) compared with chemotherapy in patients with. Pembrolizumab (n=154) compared with standard of care (soc;

Pembrolizumab (keytruda) continued to demonstrate at trend toward improved overall survival (os) compared with chemotherapy in patients with. Pembrolizumab (n=154) compared with standard of care (soc;